Skip to main content

ECCMID | Abstract Book | April 2020

By

ECCMID Abstract Book | April 2020 Preclinical Efficacy, Pharmacokinetics, and Safety of CD377, a Novel Antiviral Fc-Conjugate Against Influenza [Abstract 5126] CD377, a Novel Antiviral Fc-Conjugate, Demonstrates Superior Reduction of Viral Burden and Cytokine Levels Compared to Oseltamivir in a Lethal Mouse Model of Influenza A (H1N1) Infection [Abstract 8839] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Seasonal Influenza in Lethal Mouse Models [Abstract 5793] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Influenza…

Read More

ECCMID | Abstract Book | April 2020

By

ECCMID Abstract Book | April 2020 Analysis of Early Outcomes in the STRIVE Trial of Rezafungin Once-Weekly Treatment of Candidemia and Invasive-Candidiasis (IC) [Abstract 8845] Analysis of Outcomes by Geographic Region of Enrollment in STRIVE, the Phase 2 of Rezafungin for the Treatment of Candidemia and Invasive-Candidiasis (IC) [Abstract 5926] Evaluation of the Efficacy of Rezafungin in the Treatment of Candida albicans Endophthalmitis Using a Rabbit Model [Abstract 7523]

Read More

TIMM | Nice, France | October 2019

By

TIMM Nice, France | October 2019 RZF in vitro Activity Against Phase 2 STRIVE Part A and Contemporary Nordic Clinical Candida Isolates Determined by the EUCAST Reference Method [465] Comparison of Killing Activity of Rezafungin, Anidulafungin, Caspofungin and Micafungin against Candida auris in the presence and absence of serum [534] Frequency of Paradoxical and Trailing Effects with Rezafungin, Anidulafungin, Caspofungin and Micafungin Against Candida Species [538] Rezafungin Clinical Safety and Efficacy in the Treatment of Candidemia and/or Invasive-Candidiasis: Combined Results from the…

Read More

IDWeek | Washington, D.C. | October 2019

By

IDWeek Washington, D.C. | October 2019 Potent in vitro Activity of Rezafungin (RZF) against Aspergillus Clinical Isolates Recovered from Lung Transplant Patients who have Received ≥3 Months of Triazole Prophylaxis [738] Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018 [2115]

Read More

Options X | Singapore | August 2019

By

Options X Singapore | August 2019 Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, against Influenza A (H1N1) In a Lethal Mouse Model of Severe Combined Immunodeficiency (SCID) [11760] Preclinical Efficacy, Pharmacokinetics, and Safety of CB-012, A Novel Antiviral Fc-Conjugate against Influenza [10973] Novel Antiviral Fc-Conjugate CB-012 Demonstrates Potent Activity in Cytopathic Effect (CPE) and Viral Growth Inhibition Assays against Influenza A and B Strains [10974] Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, in Lethal Mouse Models…

Read More

ASM Microbe | San Francisco, CA | June 2019

By

ASM Microbe San Francisco, CA | June 2019 Disk Diffusion Testing of the Novel Echinocandin Rezafungin against Candida spp. – Broth vs. Disk Correlation and Quality Control [FRIDAY- AAR-687] Rezafungin is Efficacious against Invasive Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Harboring the TR34/L98H Mutation [SUNDAY- AAR-638] Rezafungin (CD101) [Antifungals New and Near symposium presentation] Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin for Treatment of Candida Infections Poster [SATURDAY-AAR-736] Oral Presentation of Poster

Read More